Abstract

Fenchone is a bicyclic monoterpene found in a variety of aromatic plants, including Foeniculum vulgare and Peumus boldus, and is used in the management of airways disorders. This study aimed to explore the bronchodilator effect of fenchone using guinea pig tracheal muscles as an ex vivo model and in silico studies. A concentration-mediated tracheal relaxant effect of fenchone was evaluated using isolated guinea pig trachea mounted in an organ bath provided with physiological conditions. Sustained contractions were achieved using low K+ (25 mM), high K+ (80 mM), and carbamylcholine (CCh; 1 µM), and fenchone inhibitory concentration–response curves (CRCs) were obtained against these contractions. Fenchone selectively inhibited with higher potency contractions evoked by low K+ compared to high K+ with resultant EC50 values of 0.62 mg/mL (0.58–0.72; n = 5) and 6.44 mg/mL (5.86–7.32; n = 5), respectively. Verapamil (VRP) inhibited both low and high K+ contractions at similar concentrations. Pre-incubation of the tracheal tissues with K+ channel blockers such as glibenclamide (Gb), 4-aminopyridine (4-AP), and tetraethylammonium (TEA) significantly shifted the inhibitory CRCs of fenchone to the right towards higher doses. Fenchone also inhibited CCh-mediated contractions at comparable potency to its effect against high K+ [6.28 mg/mL (5.88–6.42, n = 4); CCh] and [6.44 mg/mL (5.86–7.32; n = 5); high K+]. A similar pattern was obtained with papaverine (PPV), a phosphodiesterase (PDE), and Ca2+ inhibitor which inhibited both CCh and high K+ at similar concentrations [10.46 µM (9.82–11.22, n = 4); CCh] and [10.28 µM (9.18–11.36; n = 5); high K+]. However, verapamil, a standard Ca2+ channel blocker, showed selectively higher potency against high K+ compared to CCh-mediated contractions with respective EC50 values of 0.84 mg/mL (0.82–0.96; n = 5) 14.46 mg/mL (12.24–16.38, n = 4). The PDE-inhibitory action of fenchone was further confirmed when its pre-incubation at 3 and 5 mg/mL potentiated and shifted the isoprenaline inhibitory CRCs towards the left, similar to papaverine, whereas the Ca2+ inhibitory-like action of fenchone pretreated tracheal tissues were authenticated by the rightward shift of Ca2+ CRCs with suppression of maximum response, similar to verapamil, a standard Ca2+ channel blocker. Fenchone showed a spasmolytic effect in isolated trachea mediated predominantly by K+ channel activation followed by dual inhibition of PDE and Ca2+ channels. Further in silico molecular docking studies provided the insight for binding of fenchone with Ca2+ channel (−5.3 kcal/mol) and K+ channel (−5.7), which also endorsed the idea of dual inhibition.

Highlights

  • Bronchodilators are used to treat respiratory disorders such as asthma and chronic obstructive pulmonary disease (COPD), both acutely and on a long-term basis. [1,2]

  • Results observed higher potency against low K+ and fenchone was tested for its spasmolytic effect in the presence of different K+ channel antagonists (Figure 2)

  • We discovered that spasmolytic effects of natural compounds are usually mediated via K+ channel opening [35], PDE-inhibition [36], and/or Ca2+ channel blockade [37] the tracheal relaxant effects of fenchone were tested against sustained contractions induced by low K+ (25 mM), high

Read more

Summary

Introduction

Bronchodilators are used to treat respiratory disorders such as asthma and chronic obstructive pulmonary disease (COPD), both acutely and on a long-term basis. [1,2]. Current drugs used as the bronchodilator for the management of COPD, such as anticholinergic agents that were introduced to Western medicine in the early 1800s [5], have major limitations such as dry mouth, blurred vision, nausea, decreased gut mobility, urinary retention, and tachycardia. Due to these side effects, anticholinergics were displaced by adrenergic agonists in the 1920s [6]. Based on the reported result of the spasmolytic potential of monoterpene in different smooth muscles, fenchone was selected for this study to test its possible bronchodilator effect using isolated tracheal smooth muscles of guinea pigs and to probe the detailed pharmacodynamics using ex vivo and in silico molecular docking models

Objectives
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call